C2N Diagnostics specializes in developing innovative diagnostic solutions for Alzheimer’s disease and related neurodegenerative conditions, utilizing advanced technologies such as liquid chromatography-tandem mass spectrometry (LC-MS/MS). Their flagship products, the PrecivityAD® and PrecivityAD2™ blood tests, are designed to detect amyloid plaques in the brain, a key indicator of Alzheimer’s disease. These tests leverage high-resolution mass spectrometry to provide accurate and sensitive measurements of biomarkers, facilitating clinical decision-making and improving patient care. C2N's proprietary platforms, including the Stable Isotope Spike Absolute Quantification (SISAQ™) and Stable Isotope Labeling Kinetic (SILK™), enhance the precision of biomarker quantification and enable the monitoring of protein metabolism, which is crucial for understanding disease mechanisms and evaluating therapeutic targets.

In addition to their diagnostic capabilities, C2N Diagnostics is committed to advancing research in neurodegeneration through collaborations with leading academic institutions and pharmaceutical companies. Their technologies not only support clinical trials for new treatments but also contribute to epidemiological studies aimed at improving public health outcomes. The company’s ongoing efforts to expand access to their testing services globally, including partnerships with organizations like Unilabs, underscore their mission to provide less invasive and more accessible diagnostic options for patients with cognitive impairments. By focusing on high-performance testing and innovative biomarker development, C2N Diagnostics aims to transform the landscape of Alzheimer’s disease diagnosis and management.

United States

C2N Diagnostics is a molecular diagnostics company aiming to transform the early diagnosis and early treatment of Alzheimer's disease and related forms of dementia. They are developing and accelerating novel diagnostics and therapies for Alzheimer's disease, including the new PrecivityAD™ blood test for Alzheimer's disease.

C2N Diagnostics

Company Details